Topiroxostat
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Topiroxostat
- Topiroxostat: From Xanthine Oxidoreductase Inhibition to Renal Hypouricemia (Exercise-Induced AKI Prevention)
Topiroxostat: From Xanthine Oxidoreductase Inhibition to Renal Hypouricemia (Exercise-Induced AKI Prevention)
One-Sentence Summary
Topiroxostat’s original indication is not recorded in this evidence pack (not marketed in India, no CDSCO license data available), but it is known as a xanthine oxidoreductase (xanthine oxidase) inhibitor. The TxGNN model predicts it may be relevant to renal hypouricemia (RHUC1), with 0 clinical trials and 1 preclinical publication currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no CDSCO license records; original_indications field empty) |
| Predicted New Indication | Hypouricemia, renal (Renal Hypouricemia Type 1) |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L4 (single preclinical/mechanistic animal study) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (DrugBank MOA field: Data Gap). Based on the supporting literature, however, Topiroxostat is understood to act as a xanthine oxidoreductase (xanthine oxidase) inhibitor, a drug class that blocks the terminal steps of purine catabolism (hypoxanthine → xanthine → uric acid).
The predicted indication, renal hypouricemia (RHUC1), is not a condition of excess uric acid — it is caused by loss-of-function mutations in the URAT1/SLC22A12 urate transporter, leading to abnormally low serum uric acid and a predisposition to exercise-induced acute kidney injury (EIAKI). The supporting study (PMID 34799437) used a high-HPRT-activity Urat1-Uox double knockout mouse model of RHUC1 and found that xanthine oxidoreductase inhibitors suppressed the onset of EIAKI. The proposed mechanism is not uric-acid lowering (uric acid is already low in these patients), but rather reduction of oxidative purine flux and reactive oxygen species generation during high-turnover states such as intense exercise, which appears to drive the acute kidney injury.
This gives a plausible, mechanism-based rationale for TxGNN’s high similarity score: Topiroxostat shares the same enzymatic target (xanthine oxidoreductase) as the inhibitors tested in the animal model. However, this rationale currently rests on a single preclinical mouse study with no human clinical trial replication, so the mechanistic link — while biologically coherent — remains unconfirmed in patients.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34799437 | 2022 | Preclinical (animal model) | Journal of the American Society of Nephrology (JASN) | In a high-HPRT-activity Urat1-Uox double knockout mouse model of hereditary renal hypouricemia type 1 (RHUC1), xanthine oxidoreductase inhibitors suppressed the onset of exercise-induced acute kidney injury (EIAKI), supporting a role for XOR inhibition in preventing this RHUC1 complication. |
India Market Information
Topiroxostat is currently not marketed in India — no CDSCO license/registration records are available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Note: Key warnings, contraindications, and drug-drug interaction data are marked as data gaps in this evidence pack (DG001, flagged as Blocking severity — “cannot proceed to S1 safety pre-assessment” without CDSCO/TFDA label data).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a single preclinical animal study with no clinical trials, registered ICTRP trials, or human data supporting the renal hypouricemia indication. Combined with unresolved MOA data and a Blocking-severity safety data gap (no label warnings/contraindications available), there is insufficient evidence to proceed to safety pre-assessment (S1) at this time.
To proceed, the following is needed:
- Official product label warnings and contraindications (DG001, Blocking — required before S1 safety pre-assessment)
- Confirmed mechanism of action from DrugBank or primary literature (DG002)
- Clinical or human translational evidence for the renal hypouricemia / exercise-induced AKI indication (current evidence is animal-model only)
- Drug-drug interaction data (currently not found)
- Confirmation of India market/registration status, since the drug is not currently marketed under CDSCO
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.